We present some of the most interesting therapeutic applications based on these approaches and, on PRGF technology in particular, in addition to the limitations, future challenges and directions of the field.
To evaluate the biological outcomes of plasma rich in growth factors (PRGF) on human endometrial fibroblasts in culture.
Recently, a nonrandomized, prospective, longitudinal study on 808 patients indicated no adverse effects following injection of PRGF into the knee joint at 6 months [ 165].
As shown in the preceding study [12], PRP preparations exerted a biophasic effect with the maximal effects observed at 2.5 %, while in PRGF preparations, A-PRFext and CGFext stimulated cell proliferation in a dose-dependent manner (0.625 10 %).
IL-1β in PRGF preparations was under detectable levels, while it showed a similar level in other three preparations.
Numbers of platelets in PRP and PRGF preparations are shown in Fig. 1 (upper panel).
Because both IL-1β and IL-6 are known to be produced by WBCs [23], and because WBCs are not included in PRGF preparations, we thought that the bi-phasic effects of PRP preparations may be attributed to WBCs.
Endogenous regenerative technology, PRGF (plasma rich in growth factor -Endoret, is designed factor -Endorety of a complex pool of patisnt's own active morphogens that may stimulate tissue regeneration.
The rate of response to PRGF was higher in all outcome measures, although no significant differences were found; however, compared with the rate of response to HA, the rate of response to PRGF (primary outcome measure) was 14.1 percentage points significantly higher.
They used a P-PRP prepared following Anitua's technique (PRGF, "preparation rich in growth factors" or plasma-rich growth factors or platelet rich growth factors) and administered 3 intra-articular injections of autologous PRGF at 2 week intervals.
To overcome these drawbacks, Anitua developed plasma rich in growth factors (PRGF) by modifying the procedure of PRP preparation [2].
